Literature DB >> 33822008

Astrocytic glycogen accumulation drives the pathophysiology of neurodegeneration in Lafora disease.

Jordi Duran1,2, Arnau Hervera3,4,5,6, Kia H Markussen7, Olga Varea1, Iliana López-Soldado1, Ramon C Sun8, Jose Antonio Del Río3,4,5,6, Matthew S Gentry7, Joan J Guinovart1,2,9.   

Abstract

The hallmark of Lafora disease, a fatal neurodegenerative disorder, is the accumulation of intracellular glycogen aggregates called Lafora bodies. Until recently, it was widely believed that brain Lafora bodies were present exclusively in neurons and thus that Lafora disease pathology derived from their accumulation in this cell population. However, recent evidence indicates that Lafora bodies are also present in astrocytes. To define the role of astrocytic Lafora bodies in Lafora disease pathology, we deleted glycogen synthase specifically from astrocytes in a mouse model of the disease (malinKO). Strikingly, blocking glycogen synthesis in astrocytes-thus impeding Lafora bodies accumulation in this cell type-prevented the increase in neurodegeneration markers, autophagy impairment, and metabolic changes characteristic of the malinKO model. Conversely, mice that over-accumulate glycogen in astrocytes showed an increase in these markers. These results unveil the deleterious consequences of the deregulation of glycogen metabolism in astrocytes and change the perspective that Lafora disease is caused solely by alterations in neurons.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Lafora disease; epilepsy; glycogen; neurodegeneration; neuroinflammation

Mesh:

Substances:

Year:  2021        PMID: 33822008      PMCID: PMC8418345          DOI: 10.1093/brain/awab110

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  4 in total

1.  Malin restoration as proof of concept for gene therapy for Lafora disease.

Authors:  Olga Varea; Joan J Guinovart; Jordi Duran
Journal:  Brain Commun       Date:  2022-06-23

2.  Trehalose Treatment in Zebrafish Model of Lafora Disease.

Authors:  Stefania Della Vecchia; Asahi Ogi; Rosario Licitra; Francesca Abramo; Gabriele Nardi; Serena Mero; Silvia Landi; Roberta Battini; Federico Sicca; Gian Michele Ratto; Filippo Maria Santorelli; Maria Marchese
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

3.  Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora.

Authors:  Pasquale Pellegrini; Arnau Hervera; Olga Varea; M Kathryn Brewer; Iliana López-Soldado; Anna Guitart; Mònica Aguilera; Neus Prats; José Antonio Del Río; Joan J Guinovart; Jordi Duran
Journal:  Mol Neurobiol       Date:  2021-12-28       Impact factor: 5.590

Review 4.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.